Stockpolly
Search
Delisting risk
MDCX · NASDAQ · Biotechnology

Medicus Pharma (MDCX)

Develops clinical-stage therapies for skin cancer, urology, oncology, and women’s health.

$0.2600
Pre-market+0.00 (+0.89%)
At close$0.2577(+2.59%)
Watchlist

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Cost of revenue000000000000
Gross profit000000000000
0224325615868
Research & development0001112110335
021321355567
General & administrative001301355567
Other expenses0000000000−2−3
Operating income0−2−2−4−3−2−5−6−15−8−6−8
−3−1000000−1000
Interest income000000000000
Interest expense000001000000
Other non-operating income21000−1001010
Income before tax−3−3−2−4−3−2−5−6−16−8−7−8
Net income from continuing operations−3−3−2−4−3−2−5−6−16−8−7−8
Other adjustments000000000000
Net income−3−3−2−4−3−2−5−6−16−8−7−8
EPS, basic−$1.47−$0.23−$0.16−$0.33−$0.18−$0.14−$0.29−$0.31−$0.82−$0.43−$0.22−$0.15
EPS, diluted−$0.59−$0.23−$0.16−$0.33−$0.18−$0.14−$0.29−$0.31−$0.82−$0.43−$0.22−$0.15
Weighted average shares, basic28881012121419253055
Weighted average shares, diluted58881012121419253055
EBITDA−3−3−2−4−3−1−5−6−16−8−7−8
Depreciation & amortization000000000000
EBIT−3−3−2−4−3−1−5−6−16−8−7−8